Show simple item record

dc.contributor.authorKaret, F.E.
dc.contributor.authorDickerson, Claire
dc.contributor.authorBrown, J.
dc.contributor.authorBrown, M.J.
dc.identifier.citationKaret , F E , Dickerson , C , Brown , J & Brown , M J 1994 , ' Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure ' , Lancet , vol. 344 , no. 8932 , pp. 1263-1265 .
dc.identifier.otherPURE: 105978
dc.identifier.otherPURE UUID: 7ae1886e-b464-4139-9faa-43d61d726ea6
dc.identifier.otherdspace: 2299/4503
dc.identifier.otherScopus: 0027970013
dc.descriptionOriginal article can be found at: Copyright Elsevier Ltd. [Full text of this article is not available in the UHRA]
dc.description.abstractThe consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.en
dc.titleBovril and moclobemide: a novel therapeutic strategy for central autonomic failureen
dc.contributor.institutionSchool of Education
dc.description.statusPeer reviewed
rioxxterms.typeJournal Article/Review

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record